Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 17/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | ULK1 | O75385 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179503 | 0.84 | KDR (0.46) | LRRK2CYP1A2ULK1CDK1CDK4 | |
| SCHEMBL179404 | 0.84 | KDR (0.46) | LRRK2CYP1A2ULK1CDK1CDK4 | |
| SCHEMBL179515 | 0.84 | KDR (0.46) | LRRK2CYP1A2ULK1CDK1CDK4 | |
| SCHEMBL25529316 | 0.75 | LRRK2 (0.47) | LRRK2CYP1A2TTKULK1 | |
| SCHEMBL11916190 | 0.71 | LRRK2 (0.44) | LRRK2CYP1A2 | |
| SCHEMBL179485 | 0.70 | KDR (0.47) | LRRK2CYP1A2ULK1CDK1CDK4 | |
| SCHEMBL179379 | 0.70 | KDR (0.47) | LRRK2CYP1A2ULK1CDK1CDK4 | |
| SCHEMBL179442 | 0.70 | KDR (0.47) | LRRK2CYP1A2ULK1CDK1CDK4 | |
| SCHEMBL12187088 | 0.68 | AURKA (0.48) | LRRK2CYP1A2ULK1CDK1CDK4 | |
| SCHEMBL15354449 | 0.68 | AURKA (0.48) | LRRK2CYP1A2ULK1CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522146-B2 | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2016-12-20 | — | — | US | disclosed |
| US-8569323-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | LRRK2 712/4885CYP1A2 1763/4885TTK 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.